Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer – A systematic review and network meta-analysis of 3024 participants

Lung Cancer

Volumn 115, Issue , 2018, Pages 84-88

  Tan, Pui San ^a   Aguiar, Pedro ^b   Haaland, Benjamin ^c   Lopes, Gilberto ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

Immune checkpoint inhibitors; Meta analysis; NSCLC; PD L1

Indexed keywords

ATEZOLIZUMAB; DOCETAXEL; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CANCER STAGING; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; MORTALITY; NETWORK META-ANALYSIS; PROCEDURES; SURVIVAL ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DOCETAXEL; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; NEOPLASM STAGING; NETWORK META-ANALYSIS; SURVIVAL ANALYSIS;

EID: 85035770376     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.11.017     Document Type: Article

References (19)

1. Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–86.
2. Parkin, D.M., Bray, F., Ferlay, J., Pisani, P., Global cancer statistics, 2002. CA. Cancer J. Clin. 55 (2005), 74–108.
3. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA. Cancer J. Clin. 66 (2016), 7–30.
4. Schiller, J.H., Harrington, D., Belani, C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346 (2002), 92–98.
5. Patel, J.D., Socinski, M.A., Garon, E.B., et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB o. J. Clin. Oncol. 31 (2013), 4349–4357.
6. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
7. Lawrence, M.S., Stojanov, P., Polak, P., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (2013), 214–218.
8. Chen, D.S., Irving, B.A., Hodi, F.S., Molecular pathways: next-generation immunotherapy?inhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer Res. 18 (2012), 6580–6587.
9. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell lung cancer. N. Engl. J. Med. 373 (2015), 1627–1639.
10. Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-Cell non-Small-Cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
11. Herbst, R.S., Baas, P., Kim, D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387 (2016), 1540–1550.
12. Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
13. Rittmeyer, A., Barlesi, F., Waterkamp, D., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (2017), 255–265.
14. FDA, Adds Immunotherapy Approvals for Lung Cancer ? National Cancer Institute. Natl. Cancer Inst. 2017 https://www.cancer.gov/news-events/cancer-currents-blog/2016/fda-atezolizumab-pembrolizumab-lung (accessed 29.04.17).
15. Salanti, G., Ades, A., Ioannidis, J.P., Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64 (2011), 163–171.
16. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med., 6, 2009, e1000097.
17. Hirsch, F.R., McElhinny, A., Stanforth, D., et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the ‘Blueprint PD-L1 IHC assay comparison project’. J. Thorac. Oncol. 12 (2016), 208–222.
18. Salanti, G., Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 3 (2012), 80–97.
19. Ledford, H., Immunotherapy's cancer remit widens. Nature, 497, 2013, 544.